Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
{{output}}
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz) requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee (G-BA). In case no head-to-head... ...
